Back to Journals » Infection and Drug Resistance » Volume 12

Evaluation of treatment options for methicillin-resistant Staphylococcus aureus infections in the obese patient

Authors Narayanan N, Adams CD, Kubiak DW, Cheng S, Stoianovici R, Kagan L, Brunetti L

Received 28 November 2018

Accepted for publication 12 February 2019

Published 17 April 2019 Volume 2019:12 Pages 877—891

DOI https://doi.org/10.2147/IDR.S196264

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 5

Editor who approved publication: Professor Suresh Antony


Navaneeth Narayanan,1,2 Christopher D Adams,1 David W Kubiak,3 Serena Cheng,4 Robyn Stoianovici,5 Leonid Kagan,1,6 Luigi Brunetti1,6

1Department of Pharmacy Practice, Rutgers University, Ernest Mario School of Pharmacy, Piscataway, NJ, USA; 2Division of Infectious Diseases, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA; 3Department of Pharmacy, Brigham and Women’s Hospital, Boston, MA, USA; 4Department of Pharmacy, VA San Diego Healthcare System, San Diego, CA, USA; 5Department of Pharmacy, University of California, Davis Medical Center, Sacramento, CA, USA; 6Department of Pharmaceutics, Rutgers University, Ernest Mario School of Pharmacy, Piscataway, NJ, USA

Abstract: Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a major cause of infection in both the hospital and community setting. Obesity is a risk factor for infection, and the prevalence of this disease has reached epidemic proportions worldwide. Treatment of infections in this special population is a challenge given the lack of data on the optimal antibiotic choice and dosing strategies, particularly for treatment of MRSA infections. Obesity is associated with various physiological changes that may lead to altered pharmacokinetic parameters. These changes include altered drug biodistribution, elimination, and absorption. This review provides clinicians with a summary of the literature pertaining to the pharmacokinetic and pharmacodynamic considerations when selecting antibiotic therapy for the treatment of MRSA infections in obese patients.

Keywords: obesity, methicillin-resistant Staphylococcus aureus, antibiotics, pharmacokinetics

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]